A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL

CD19-directed chimeric antigen receptor (CAR) T cells have yielded impressive response rates in refractory/relapse B cell acute lymphoblastic leukemia (B-ALL); however, most patients ultimately relapse due to poor CAR T cell persistence or resistance of either CD19(+) or CD19(−) B-ALL clones. CD22 i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zanetti, Samanta Romina, Velasco-Hernandez, Talia, Gutierrez-Agüera, Francisco, Díaz, Víctor M., Romecín, Paola Alejandra, Roca-Ho, Heleia, Sánchez-Martínez, Diego, Tirado, Néstor, Baroni, Matteo Libero, Petazzi, Paolo, Torres-Ruiz, Raúl, Molina, Oscar, Bataller, Alex, Fuster, José Luis, Ballerini, Paola, Juan, Manel, Jeremias, Irmela, Bueno, Clara, Menéndez, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821938/
https://www.ncbi.nlm.nih.gov/pubmed/34478871
http://dx.doi.org/10.1016/j.ymthe.2021.08.033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821938/
https://www.ncbi.nlm.nih.gov/pubmed/34478871
http://dx.doi.org/10.1016/j.ymthe.2021.08.033

Ejemplares similares